Key facts
- This page summarizes Lowell Thomas Holden's Form 4 filing for Nascent Biotech Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2024, 08:51.
Lowell Thomas Holden - 30 Jun 2024 Form 4 Insider Report for Nascent Biotech Inc.
- Reporting relationship
- CFO, Director
- Issuer ticker
- N/A
- Reported as of
- 30 Jun 2024
- Net transaction value
- +$8,640
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2024, 08:51:08 UTC
- Prior SEC filing
- 10 Apr 2024
- Next SEC filing
- 06 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lowell Holden
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lowell Thomas Holden filed Form 4 for Nascent Biotech Inc. on 02 Jul 2024.
Change
- Previous filing in this sequence was filed on 10 Apr 2024.
- Current net transaction value: +$8,640.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NBIO
transaction
Common stock
Other
- Transaction value
- $8,640
- Shares
- +96,000
- Change %
- +0.97%
- Price
- $0.0900
- Shares after
- 10,005,477
- Date
- 30 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares were granted as part of the employment contract with the Company.